Lazard Capital Initiates Coverage on Athersys (ATHX) with a Buy
More News related to ATHX
- Athersys Reports 2008 Second Quarter Results
- Athersys to Present At Canaccord Adams 28th Annual Global Growth Conference
- Athersys to Host Second Quarter 2008 Financial Results Call
- Athersys Added to Russell Microcap Index
- Lazard Capital Initiates Coverage on Athersys (ATHX) with a Buy
More News related to New Coverage
- CASP Urges Immediate Action on National Suicide Prevention Strategy
- New Jobless Numbers Push Misery Index Up to 11.7 Percent
- Texas Petrochemicals Announces Fiscal 2008 Fourth Quarter Earnings and Conference Call Schedule
- CASP Urges Immediate Action on National Suicide Prevention Strategy
- Media Advisory: Our Fallen Soldiers Return Home
Lazard Capital initiates coverage on Athersys (Nasdaq: ATHX) with a Buy. Price target $7.
Athersys, Inc. is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
